|NASDAQ: ATHX||Healthcare / Biotechnology / USA|
|1.40||+0.2200||+18.64%||Vol 617.07K||1Y Perf -93.28%|
|Mar 22nd, 2023 14:00 DELAYED|
|0.07 5.93%||- -|
|Target Price||0.40||Analyst Rating||Moderate Sell 4.00|
|Potential %||-71.83||Finscreener Ranking||☆ 25.00|
|Insiders Trans % 3/6/12 mo.||-/100/20||Value Ranking||☆ 19.77|
|Insiders Value % 3/6/12 mo.||-/100/41||Growth Ranking||☆ 6.52|
|Insiders Shares Cnt. % 3/6/12 mo.||-/100/59||Income Ranking||— -|
|Price Range Ratio 52W %||2.74||Earnings Rating||Strong Sell|
|Market Cap||24.09M||Earnings Date||21st Mar 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||110.63K|
|Avg. Monthly Volume||114.50K|
|Avg. Quarterly Volume||275.41K|
Athersys Inc. (NASDAQ: ATHX) stock closed at 1.18 per share at the end of the most recent trading day (a 0.85% change compared to the prior day closing price) with a volume of 74.56K shares and market capitalization of 24.09M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 104 people. Athersys Inc. CEO is Daniel A. Camardo.
The one-year performance of Athersys Inc. stock is -93.28%, while year-to-date (YTD) performance is 40.48%. ATHX stock has a five-year performance of -97.57%. Its 52-week range is between 0.5031 and 33.25, which gives ATHX stock a 52-week price range ratio of 2.74%
Athersys Inc. currently has a PE ratio of 0.20, a price-to-book (PB) ratio of 219.57, a price-to-sale (PS) ratio of 3.54, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -168.19%, a ROC of -519.68% and a ROE of -1 970.03%. The company’s profit margin is -%, its EBITDA margin is -1 384.70%, and its revenue ttm is $5.29 Million , which makes it $0.31 revenue per share.
Of the last four earnings reports from Athersys Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Athersys Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Athersys Inc. is Moderate Sell (4), with a target price of $0.4, which is -71.83% compared to the current price. The earnings rating for Athersys Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Athersys Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Athersys Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 28.88, ATR14 : 0.13, CCI20 : -232.22, Chaikin Money Flow : -0.18, MACD : -0.06, Money Flow Index : 41.09, ROC : -22.88, RSI : 34.24, STOCH (14,3) : 2.13, STOCH RSI : 0.05, UO : 30.35, Williams %R : -97.87), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Athersys Inc. in the last 12-months were: Daniel A. Camardo (Buy at a value of $54 960)
|Analyst Ratings||Current||1 M ago||3 M ago|
|Summary Rating||Moderate Sell||Moderate Sell||Moderate Sell|
Athersys Inc is a biotechnology company. It is focused on developing novel and proprietary therapies in the areas where there is an unmet medical need, particularly in the regenerative medicine area. The firm's main product is Multistem cell therapy. Its current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders and certain pulmonary conditions. Its revenue has been derived from corporate collaborations, license agreements, and government grants.
CEO: Daniel A. Camardo
Telephone: +1 216 431-9900
Address: 3201 Carnegie Avenue, Cleveland 44115-2634, OH, US
Number of employees: 104
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.